AutoRegenic Immunologics is a precision biomedicine research and development company that is productizing tissue regeneration treatments for immunodeficiency diseases—like sickle cell anemia and blood cancers—based on its manufacturing, specialization and formulation of “rebirthed” stem cells. Sickle cell disease affects millions of people of African origin worldwide, killing over 115,000 each year. Blood cancer attacks over 1.2 million people and claims around 700,000 lives per year.
AutoRegenic cell manufacturing is designed to be a safe, effective, ethically balanced, and affordable GMP process that encompasses performing somatic cell nuclear transfer (SCNT) to develop naïve pluripotent stem cells that may be differentiated into generous doses of youthful hematopoietic (blood-generating) stem cells to refurbish patients’ faulty immune systems.
The AutoRegenic biomedicine will be both broad and precise, treating the very source of the diseases, rather than their cascade of secondary effects. The lab service aims to address three critical challenges in treating immunodeficiency and blood diseases:
(1) establish a massive cryo-repository of high-resolution profiled donor stem cells with a compensatory bias towards African origins;
(2) employ a smart registry (AI) and machine learning to match the best biomedicines and transplant techniques to patients; and
(3) provide ample volumes of vital, personalized hematopoietic stem cell doses for patients.
Our team is comprised of experienced entrepreneurs from the biomedical, pharmaceutical, blood donor, technology, regulatory and marketing fields, supported by a world-class scientific advisory board, including international experts in the field of regenerative medicine and transplantation, and uniquely skilled laboratory technicians.
We are busy productizing an unique set of laboratory techniques, processes, materials, and international logistics for producing naive pluripotent stem cells that promise to become a safe, effective, ethically balanced and affordable innovation of blood stem cell sourcing and transplants on a patient-specific basis.
Following years of insights into applied R&D, the leadership team has defined a path for validation of the underlying science, pre-clinical testing and clinical trialing of the biomedicine and has assembled a set luminary supporters and advisory spanning the scientific and medical academic as well as clinical practice fields.